Heart attack prevention shot tested in 16,000 patients
NCT ID NCT03705234
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This large phase 3 study tests a new cholesterol-lowering injection called inclisiran in over 16,000 people who have already had a heart attack, stroke, or artery surgery. The goal is to see if it safely reduces the risk of future heart attacks, strokes, or the need for emergency procedures. Participants receive either the injection or a placebo, and researchers track major heart events over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CTSU, University of Oxford
Oxford, Oxfordshire, OX3 7LF, United Kingdom
-
TIMI Study Group
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your smartwatch may predict a heart attack days before it happens
- Could an arthritis drug shield heart and kidneys in metabolic syndrome?
- Heart drug showdown: which statin spares your blood sugar?
- 3,000 volunteers to reveal hidden heart risks in qatar
- Which drug lowers cholesterol better? new study compares alirocumab and inclisiran
- Can extremely low cholesterol save more hearts? new trial aims to find out